Loading…
Therapeutic Hemp Medical Access Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Therapeutic Hemp Medical Access Act of 2015 Amends the Controlled Substances Act to exclude cannabidiol and cannabidiol-rich plants: (1) from the definition of "marihuana," and (2) from treatment as a controlled substance under such Act. Defines: (1) "cannabidiol-rich plant" to mean the plant Cannabis sativa L. and any part of such plant with a tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis; (2) "cannabidiol" to mean the substance cannabidiol, as derived from a cannabidiol-rich plant; and (3) "tetrahydrocannabinol concentration" to mean the percent of the delta-9 tetrahydrocannabinol content per dry weight of any part of the plant Cannabis sativa L. or per volume of weight of marihuana product, or the combined percent of the delta-9 tetrahydrocannabinol and tetrahydrocannabinolic acid in any part of the plant Cannabis sativa L., regardless of moisture content. Declares that nothing in this Act shall be construed to restrict any activities related to the use, production, or distribution of marihuana in a state in which such activities are legal under state law.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Health Issues
FDA and DEA regulation of cannabidiol; monitor S. 1333 (Therapeutic Hemp Medical Access Act of 2015), HR 1635 (Charlotte's Web Medical Access Act of 2015), S. 683/S. 1538 (Compassionate Access, Research Expansion and Respect States Act) and activity related to medical marijuana research
Client expense: Not reported · Firm income: $10,000
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · third_quarter · Health Issues
FDA and DEA regulation of cannabidiol; monitor S. 1333 (Therapeutic Hemp Medical Access Act of 2015), HR 1635 (Charlotte's Web Medical Access Act of 2015), S. 683/S. 1538 (Compassionate Access, Research Expansion and Respect States Act) and activity related to medical marijuana research
Client expense: Not reported · Firm income: $20,000
2016 · second_quarter · Health Issues
FDA and DEA regulation of cannabidiol; monitor S. 1333 (Therapeutic Hemp Medical Access Act of 2015), HR 1635 (Charlotte's Web Medical Access Act of 2015), S. 683/S. 1538 (Compassionate Access, Research Expansion and Respect States Act) and activity related to medical marijuana research
Client expense: Not reported · Firm income: Not reported
2015 · fourth_quarter · Health Issues
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
Client expense: Not reported · Firm income: $20,000
Government targets: SENATE
2015 · fourth_quarter · Health Issues
S.1333, Therapeutic Hemp Medical Access Act of 2015, Monitor supplement related issues
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
Client expense: Not reported · Firm income: $180,000
Government targets: SENATE
2015 · third_quarter · Health Issues
S.1333, Therapeutic Hemp Medical Access Act of 2015, Monitor supplement related issues
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
Client expense: Not reported · Firm income: $20,000
Government targets: SENATE
2015 · second_quarter · Health Issues
S.1333, Therapeutic Hemp Medical Access Act of 2015, Supplement related issues
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
Client expense: Not reported · Firm income: Not reported
| Republican |
| SC |
| Mark R. Warner | Democratic | VA |
| Michael F. Bennet | Democratic | CO |
| Mike Lee | Republican | UT |
| Orrin G. Hatch | Republican | UT |
| Ron Johnson | Republican | WI |
| Ron Wyden | Democratic | OR |
| Roy Blunt | Republican | MO |
| Tammy Baldwin | Democratic | WI |
| Thom Tillis | Republican | NC |